tbuckley/cabot-search huggingface dataset:
Abstract P006: Flow-Mediated Dilation is Inversely Associated with Cardiovascular Disease Risk: a Meta-Analysis of Prospective Studies
Authors: Rouyanne T Ras, Martinette T Streppel, Peter L Zock, Richard Draijer
Journal: Circulation (2012)

Background - Flow-mediated dilation (FMD) is an accepted technique to quantify endothelial (dys)function. The predictive value of FMD for future cardiovascular disease (CVD) risk has been investigated in several prospective studies. The purpose of the present study was to systematically review these studies and to quantify the relationship between FMD and CVD risk. It was hypothesized that the risk of experiencing a cardiovascular event later in life would be smaller when having a higher FMD value at baseline. Methods - Potentially relevant prospective studies were searched in several databases and by hand searching, through March 2011. Studies were selected based on predefined selection criteria. The statistical analysis was performed separately for continuous (per 1% increase in FMD) and categorical (when having a high vs. low FMD) risk estimates for CVD. The pooled overall risk estimate was calculated based on a random-effects model while weighting each study by the inverse of its variance. Potential sources of heterogeneity were investigated as well as presence of publication bias. Results - In total, 23 studies including 14,753 subjects were eligible for inclusion in the present meta-analysis. Subjects were followed for an average duration of 42.9 months (range: 12.1-94.6 months). The average age was 60.1 years (range: 46.0-78.6 years). In 8 out of 23 studies, asymptomatic subjects were included whereas in 15 studies, subjects were diagnosed as having various forms of diseases. In studies reporting continuous risk estimates, the pooled overall risk estimate for CVD expressed per 1 % increase in FMD was 0.90 (95%CI: 0.86, 0.94). One study, that was the only study including exclusively renal patients, reported results that significantly differed from this estimate. Excluding this study from the analysis did not materially affect the pooled overall risk estimate (RR = 0.92 (95%CI: 0.88; 0.95). Based on studies with categorical risk estimates, the pooled overall risk estimate for CVD when having a high FMD vs. a low FMD was 0.49 (95%CI: 0.38, 0.63). Covariate analysis revealed that health status significantly affected the association between FMD and CVD risk with a stronger association in diseased populations. Presence of publication bias could not be excluded. Conclusions - Our findings show that baseline FMD is inversely associated with CVD risk, particularly in diseased populations. Further studies should address the impact of underlying health status on the relationship between FMD and CVD.
JOURNALS ABSTRACTED IN THE CURRENT MEDICAL LITERATURE DEPARTMENT, JANUARY-APRIL 1942
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II Study of Thymoglobulin, Cyclosporine and G-CSF for Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome
Authors: Ravi n Jain Garg, Guillermo Garcia-Manero, Stefan Faderl, Jorge Cortes, Charles Asa Koller, Miloslav Beran, Gautam Borthakur, Hagop M Kantarjian, Farhad Ravandi
Journal: Blood (2008)
Aspirin, NSAIDS, Calcium-channel blockers and statins in the aetiology of pancreatic cancer: preliminary results from a case-control study in two centres in the UK
Authors: T. F. G. Pugh, M. Little, F. Carey, M. Metcalfe, R. Robinson, A. Clark, R. Ndokera, H. Ing, A. Dennison, A. Hart
Journal: Gut (2011)

<h3>Introduction</h3> There are plausible mechanisms that carcinogenesis may be altered by: aspirin, NSAIDs, calcium-channel blockers and statins, through both inhibition of cyclo-oxygenase enzymes and the production of mediators of the cell cycle. The current epidemiological data in this area is either limited, reports conflicting results or does not consider important confounders. The aim of this study was to investigate whether there is a negative association between these medications and the development of pancreatic cancer in a case-control study in the UK. <h3>Methods</h3> Clinical management databases were used to identify patients diagnosed with pancreatic cancer managed in Norfolk (years 2004–2006) and Leicestershire (2007). The use of these medications, prior to diagnosis, was recorded from a detailed review of the medical records. The control group were 251 dermatology patients of similar ages treated for basal cell carcinoma. ORs with 95% CI, for the development of pancreatic cancer for each medication, were estimated using unconditional logistic regression and adjusted for gender, age at diagnosis, cigarette smoking and type II diabetes. <h3>Results</h3> A total of 206 cases of adenocarcinoma of the pancreas (median age=71 years, range 49–99 years, 52% women, a median survival of 3.5 months) and 251 controls were identified. Aspirin use was negatively associated with the development of pancreatic cancer (OR=0.49, 95% CI 0.29 to 0.84, p=0.01). There were no associations with either NSAIDs (OR=0.98, CI 0.50 to 1.91, p=0.95), statins (OR=0.64, CI 0.38 to 1.11, p=0.11) or calcium-channel blockers (OR=0.78, 95% CI 0.43 to 1.39, p=0.40). <h3>Conclusion</h3> The data support a protective role for aspirin, but not currently for the remaining medications in the aetiology of pancreatic cancer. The work is continuing to identify more cases and controls that may confirm our preliminary results for aspirin9s negative association and also show an effect for statins. Before aspirin can be recommended as a chemo-preventive agent, further population-based studies are required to confirm the association and provide detailed information on the dose of aspirin needed and its duration of use.
February 24, 1999
Journal: JAMA (1999)

Physicians in the United States, Canada, and MexicoPhysicians with current and valid licenses in the United States, Canada, or Mexico who read any 3 of the selected continuing medical education (CME) articles in this issue of JAMA, complete the CME Evaluation Form on the next page, and fax it to the number or mail it to the address at the bottom of the CMEEvaluationFormareeligibleforcategory1CMEcredit.Thereisnocharge.The American Medical Association (AMA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor CME for physicians.The AMA designates this educational activity for up to 1 hour of category 1 CME credit per JAMA issue toward the AMA Physician's Recognition Award (PRA).Each physician should claim for credit only those hours that were actually spent in this educational activity. Physicians in Other CountriesPhysicians with current and valid licenses in the United States, Mexico, or Canada are eligible for CME credit even if they live or practice in other countries.Physicians licensed in other countries are also welcome to participate in this CME activity.However, the PRA is available only to physicians licensed in the United States, Canada, or Mexico. Should the Electrocardiogram Be Used to Guide Therapy for Patients With Left Bundle-Branch Block and Suspected Myocardial Infarction? 714Educational Objective: To learn that thrombolysis may be indicated for stroke prevention in all patients with left bundle-branch block and chest pain. Stage at Diagnosis and Treatment Patterns Among Older Women With Breast Cancer: An HMO and Fee-for-Service Comparison 720Educational Objective: To learn that women enrolled in HMOs who develop breast cancer may be likely to receive appropriate care.
Cardiopulmonary Resuscitation
Authors: James R. Roberts
Journal: JAMA (1983)

<i>Cardiopulmonary Resuscitation</i>is a 178-page text that reviews current standards and techniques of cardiopulmonary resuscitation (CPR) and presents various new concepts and recent advances in the field. The book includes chapters on traumatic cardiac arrest, the "new" CPR, brain resuscitation, and a section on legal aspects of resuscitation as well as a review of such standard topics as defibrillation and drug therapy. A perusal of the list of contributing authors will identify an interesting mix of 17 contributors, including emergency physicians, cardiologists, anesthesiologists, radiologists, pediatricians, and a paramedic. After a brief introductory chapter is a detailed and academic discussion of ventilation during CPR. This section presents no new concepts but is a scholarly overview of basic physiology. The second half of this chapter contains basic material and includes a discussion of airway treatment, bagmask ventilation, intubation, and treatment of the obstructed airway. A review of this commonly presented material is,
Effect of prostaglandin and seminal fluid on human chorioamniotic membranes
Authors: J. P. Lavery
Journal: JAMA (1981)

Coitus during pregnancy has long been thought to be associated with adverse obstetric outcome. One critical problem in this connection is membrane rupture leading to preterm delivery. We studied 220 human chorioamniotic membranes and evaluated their tensile strength after exposure to human seminal fluid and specific prostaglandins. It was concluded that the biochemical constituents of seminal fluid do not have an adverse effect on the strength of human chorionic membranes. (<i>JAMA</i>1981;245:2425-2427)
Guide for the evaluation of hearing handicap
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HSR20-079: Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study
Authors: En Cheng, Peiyin Hung, Shi-Yi Wang
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-079: Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study" published on 20 Mar 2020 by National Comprehensive Cancer Network.
An Inquiry into the Efficacy of Digitalis in the Treatment of Idiopathic Epilepsy
Journal: BMJ (1841)

Most practitioners are aware of the obstinate nature and the deplorable consequences of epilepsy.Yet, ever)7 now and then we find it disappear, with or without remedies.Where there is no actual deformity of the skull, or imbecility of the mind, we ought to give a fair trial to medicine and diet.Whatever specific we may employ, a regulation of all the great functions is the primary and the principal object.This procedure alone, will sometimes arrest the disease or greatly prolong the intervals between the attacks.The next prominent indication is a drain, by means of a seton, from the neighbourhood of the head.These failing, recourse must be had to nostrums or specifics, as the nitrate of silver, the oxide of zinc?or, lastly, digitalis, the subject of the treatise.We are informed by Dr. Sharkey, that about nine years ago, his father published a paper in the Lancet on the Use of Digitalis in Epilepsy?butno notice has since been taken of the remedy by any authors.Some of these cases are re-stated by Dr. Sharkey, and others are added.We shall condense some of the more interesting of these.* This is surely an oversight of Dr. Sharkey's.Ten fits of epilepsy take place in the recumbent, for one in the perpendicular posture.? (Ed.)
Uganda Asians
Authors: A. W. Woodruff
Journal: BMJ (1972)

Saccades under four specific test conditions (visually guided, visually remembered, vestibular remembered, and cervical remembered) were studied in a 38 year old man with ocular dysmetria due to an angioma of the dorsal cerebellar vermis. The aim of the study was to investigate if the saccadic disorder was specific to certain subsets of saccades elicited by different sensory modalities. The experiments showed that initial saccades were equally hypermetric in all four conditions and that final eye position was normal in all memory guided saccade tests. Eye movements differed after the initial saccade, however. Whereas corrective saccades were seen in most visually guided and visually remembered experiments, postsaccadic centripetal drifts were documented in non-visual (vestibular and cervical) remembered saccades. These results indicate that the cerebellar vermis modulates the amplitude of the initial saccade (pulse size of saccadic innervation) independently of the saccadic task. The finding that post-saccadic drift never occurred when saccades were programmed using visual positional information suggests that the dorsal vermis may participate in the process of pulse step integration of saccades elicited by memorised vestibulo-cervical information.
Abstract 1295: First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer
Authors: Daksh Thaper, Ravi Munuganti, Shaghayegh Nouruzi, Sahil Kumar, Soojin Kim, Olena Sivak, Adeleke Aguda, Dwaipayan Ganguli, Sepideh Vahid, Loredana Puca, Himisha Beltran, Amina Zoubeidi
Journal: Cancer Research (2019)

Abstract Introduction: Resistance to newly developed androgen receptor pathway inhibitors (ARPIs), such as Enzalutamide (ENZ), rapidly emerges and patients generally die within two years. In particular, a subset of patients who relapse following ARPI therapy exhibit lineage switching whereby tumours shed their dependence on AR signaling and emerge with neuroendocrine features. These tumours, termed treatment induced neuroendocrine prostate cancer (t-NEPC), carry an extremely poor prognosis and, to date, treatment remains decades old cytotoxic chemotherapy which carries a short-lived response at the cost of significant toxicity. Therefore, targeted therapies for this deadly disease are desperately needed. Thus, the need to develop targeted treatments for this devastating disease is of paramount importance. Recently our group identified the neural transcription factor BRN2 as a major clinically relevant driver of NEPC and aggressive tumor growth, both in vitro and in vivo, suggesting targeting BRN2 is a promising strategy to prevent neuroendocrine differentiation or treat NEPC. Methods: Study the effects of BRN2 inhibition using siRNA, small molecule inhibitors and CRISPR K/O models. Results: Inhibition of BRN2 by siRNA and by CRISPR/Cas9 knockout drastically reduced cell proliferation in 42DENZR (NEPC) cell lines. This data was re-capitulated in human NEPC NCI-H660 cells. Loss of BRN2 initiated drastic epigenetic changes in NEPC cell lines as well as in G1 arrest through up-regulation of CDKN1A/1B. This was confirmed using our first in field BRN2 inhibitors. Targeting BRN2 also lead to downregulation several known targets in NEPC like EZH2, AURKA, SOX2 and Peg10. Treatment with BRN2i reduced recruitment of BRN2 to the chromatin by approximately 93% within 16 hours. Moreover, these BRN2 inhibitors displayed adequate pharmacokinetic properties and reduced NEPC proliferation in vivo. Conclusion: No therapies exist for highly lethal NEPC. Hence, the described work aims to verify BRN2, a central driver of NEPC, and lay the pre-clinical foundation for the integration of targeted therapies into the treatment landscape to improve survival and quality of life for patients suffering from deadly form of prostate cancer. Citation Format: Daksh Thaper, Ravi Munuganti, Shaghayegh Nouruzi, Sahil Kumar, Soojin Kim, Olena Sivak, Adeleke Aguda, Dwaipayan Ganguli, Sepideh Vahid, Loredana Puca, Himisha Beltran, Amina Zoubeidi. First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1295.
Clinical prediction scores for venous thromboembolism in patients with a hematological malignancy
Authors: Frits I. Mulder, Nick van Es
Journal: HemaSphere (2018)

1Department of Vascular Medicine, Academic Medical Center, Amsterdam 2Department of Internal Medicine, Tergooi hospital, Hilversum, The Netherlands This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CCBY-NC-ND), which allows third parties to download the abstracts and share them with others as long as they credit the author and the abstract book, but they cannot change the content in any way or use them commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
Call for experts to join the Scientific Panels of the European Food Safety Authority – deadline extended to 7 July 2014
Authors: None Eurosurveillance editorial team
Journal: Eurosurveillance (2014)

Preview this article: Call for experts to join the Scientific Panels of the European Food Safety Authority – deadline extended to 7 July 2014, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/19/23/art20827-en-1.gif
Breast Non Hodgkin’s Lymphoma (NHL): A Large Monocentric Study of Initial Characteristics, Natural History, and Prognostic Factors.
Authors: Philippe Arnaud, Bernard Asselain, Patricia Validire, Youlia Kirova, Corine Plancher, Anne Vincent-Salomon, Alain Fourquet, Rafika Sahli, Jessica Konopka, Didier Decaudin
Journal: Blood (2006)
10T1/2 Cells: An In Vitro Model for Molecular Genetic Analysis of Mesodermal Determination and Differentiation
Authors: Deborah F. Pinney, Charles P. Emerson
Journal: Environmental Health Perspectives (1989)

Progress has been made in understanding the molecular mechanisms that regulate cell type-specific gene expression during the terminal differentiation of cells into specialized tissue types. These studies have concentrated largely on defining the cis elements and trans-acting factors responsible for the transcription of differentiation-specific genes. Valuable as these investigations have been, they have not been able to place differentiation into the larger context of development, specifically into the context of the earlier developmental process of cell determination, when embryonic stem cell lineages are formed and the genetic regulatory programs for cell type-specific gene activation and expression are acquired by stem cells. The clonal mouse embryo cell line, C3H/10T1/2, clone 8 (10T1/2) provides a unique opportunity to examine the molecular genetic regulation of both the developmental determination of vertebrate stem cell lineages and their subsequent differentiation. 10T1/2 is an apparently multipotential cell line that can be converted by 5-azacytidine into three mesodermal stem cell lineages. These determined proliferative stem cells are stable in culture and retain their ability to differentiate in mitogen-depleted medium. The most significant discovery has been that 10T1/2 lineage determination is under simple genetic control and that the regulatory genes that mediate the formation of myogenic cell lineages, and likely the chondrogenic and adipogenic lineages, can be demonstrated and studied by genomic DNA and cDNA transfection approaches. This paper is a description of the remarkable properties and genetic behaviors of the 10T1/2 cells and a discussion of the insights that future studies of this cell may provide.
Ergebnisse der medizinischen Strahlenforschung. (Röntgen-diagnostik, Röntgen-, Radium- und Lichttherapie).
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Disseminated candidiasis in a patient with acute leukemia. Successful treatment with miconazole
Authors: M. E. Katz
Journal: JAMA (1977)

THE ADMINISTRATION of chemotherapy to patients with adult acute nonlymphocytic leukemia presently yields a 50% to 60% complete remission rate.<sup>1</sup>Death from infection remains a major factor in preventing a higher proportion of patients from obtaining a complete remission.<sup>2</sup>Candidiasis is the most frequent fungal infection in patients with leukemia<sup>3</sup>and is often difficult to treat despite the use of amphotericin B with or without flucytosine. Amphotericin B may cause true anaphylaxis, fever, chills, hypotension, skin rash, nausea, vomiting, anorexia, anemia, azotemia, and renal tubular acidosis.<sup>4,5</sup> Miconazole nitrate is a synthetic 1-phenethylimidazole derivative, 1-2,4-dichloro-β(2,4-dichlorobenzyloxy) phenethylimidazole nitrate with broad-spectrum antifungal and antibacterial activity.<sup>6</sup>Miconazole has been used in the treatment of coccidioidomycosis with moderate success.<sup>7</sup>Phlebitis at the site of infusion has been the only recognized side effect and can often be avoided by the use of a central venous catheter. We report here the